Li C, Moro S, Shostak K, O'Reilly FJ, Donzeau M, Graziadei A, McEwen AG, Desplancq D, Poussin-Courmontagne P, Bachelart T, Fiskin M, Berrodier N, Pichard S, Brillet K, Orfanoudakis G, Poterszman A, Torbeev V, Rappsilber J, Davey NE, Chariot A, Zanier K

Nat Commun. 2024 09 3;15(1):7692

Sites of disruption within E1 and E2 genes of HPV16 and association with cervical dysplasia.

Tsakogiannis D, Gortsilas P, Kyriakopoulou Z, Ruether IG, Dimitriou TG, Orfanoudakis G, Markoulatos P

J Med Virol. 2015 May 8

Prevalence of HPV16 E1-1374^63nt variants in Greek women.

Tsakogiannis D, Kyriakopoulou Z, Darmis F, Ruether IG, Dimitriou TG, Orfanoudakis G, Panotopoulou E, Markoulatos P

J Med Virol. 2014 May;86(5):778-84

Molecular and evolutionary analysis of HPV16 E6 and E7 genes in Greek women.

Tsakogiannis D, Papadopoulou A, Kontostathi G, Ruether IG, Kyriakopoulou Z, Dimitriou TG, Orfanoudakis G, Markoulatos P

J Med Microbiol. 2013 Nov;62(Pt 11):1688-96

Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1.

Fournane S, Charbonnier S, Chapelle A, Kieffer B, Orfanoudakis G, Trave G, Masson M, Nomine Y

J Mol Recognit. 2011 Jul-Aug;24(4):511-23

High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma.

Dalagiorgou G, Vassilaki N, Foka P, Boumlic A, Kakkanas A, Kochlios E, Khalili S, Aslanoglou E, Veletza S, Orfanoudakis G, Vassilopoulos D, Hadziyannis SJ, Koskinas J, Mavromara P

J Gen Virol. 2011 Jun;92(Pt 6):1343-51

Internal translation initiation stimulates expression of the ARF/core+1 open reading frame of HCV genotype 1b.

Boumlic A, Vassilaki N, Dalagiorgou G, Kochlios E, Kakkanas A, Georgopoulou U, Markoulatos P, Orfanoudakis G, Mavromara P

Virus Res. 2011 Jan;155(1):213-20

Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.

Bernard X, Robinson P, Nomine Y, Masson M, Charbonnier S, Ramirez-Ramos JR, Deryckere F, Trave G, Orfanoudakis G

PLoS One. 2011;6(10):e25981

Prevalence of intrinsic disorder in the hepatitis C virus ARFP/Core+1/S protein.

Boumlic A, Nomine Y, Charbonnier S, Dalagiorgou G, Vassilaki N, Kieffer B, Trave G, Mavromara P, Orfanoudakis G

FEBS J. 2010 Feb;277(3):774-89

A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.

Ristriani T, Fournane S, Orfanoudakis G, Trave G, Masson M

Oncogene. 2009 Feb 5;28(5):762-72

Defining the minimal interacting regions of the tight junction protein MAGI-1 and HPV16 E6 oncoprotein for solution structure studies.

Charbonnier S, Stier G, Orfanoudakis G, Kieffer B, Atkinson RA, Trave G

Protein Expr Purif. 2008 Jul;60(1):64-73

A novel adenovirus vector for easy cloning in the E3 region downstream of the CMV promoter.

Mailly L, Boulade-Ladame C, Orfanoudakis G, Deryckere F

Virol J. 2008 Jun 6;5:73.

Modification of adenovirus type 5 tropism for a preferential transduction of human papillomavirus-positive cancer cells.

Lagrange M, Boulade-Ladame C, Orfanoudakis G, Deryckere F

Arch Virol. 2008;153(10):1921-5

Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells.

Lagrange M, Boulade-Ladame C, Mailly L, Weiss E, Orfanoudakis G, Deryckere F

Biochem Biophys Res Commun. 2007 Sep 21;361(2):487-92

Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.

Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F, Sibler AP, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Trave G

Mol Cell. 2006 Mar 3;21(5):665-78.

Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.

Lagrange M, Charbonnier S, Orfanoudakis G, Robinson P, Zanier K, Masson M, Lutz Y, Trave G, Weiss E, Deryckere F

J Gen Virol. 2005 Apr;86(Pt 4):1001-7.